Solexa
Solexa developed next-generation genome sequencing technology to make high-speed, low-cost DNA analysis accessible for research and clinical diagnostics. It was acquired by Illumina in 2007.
About
Solexa developed systems for the comprehensive and cost-effective analysis of individual genomes, with the goal of transforming biological and medical research through rapid, affordable sequencing—a foundational capability for 21st-century science.
The company aimed to reduce the cost of human resequencing to just a few thousand dollars, ultimately achieving the ‘$1,000 genome’ for widespread use in research and clinical diagnostics.
Solexa was acquired by Illumina in January 2007. Amadeus sold its final holdings in Illumina in July 2008.
